Bindu Murthy

901 total citations
41 papers, 672 citations indexed

About

Bindu Murthy is a scholar working on Genetics, Rheumatology and Molecular Biology. According to data from OpenAlex, Bindu Murthy has authored 41 papers receiving a total of 672 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 10 papers in Rheumatology and 6 papers in Molecular Biology. Recurrent topics in Bindu Murthy's work include Systemic Lupus Erythematosus Research (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers). Bindu Murthy is often cited by papers focused on Systemic Lupus Erythematosus Research (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers). Bindu Murthy collaborates with scholars based in United States, Sweden and Germany. Bindu Murthy's co-authors include Anne Schmitt‐Hoffmann, Christopher R. Curtin, Roy E. Twyman, Dennis R. Doose, Shean‐Sheng Wang, Stefan Schwabe, Meir Bialer, Vidya Perera, Ian M. Catlett and Zhaoqing Wang and has published in prestigious journals such as Journal of the American College of Cardiology, Scientific Reports and European Heart Journal.

In The Last Decade

Bindu Murthy

36 papers receiving 656 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bindu Murthy United States	14	141	119	118	117	104	41	672
Suda Vannaprasaht Thailand	13	453 3.2×	30 0.3×	92 0.8×	172 1.5×	84 0.8×	36	853
Yamin Shu China	17	175 1.2×	45 0.4×	36 0.3×	58 0.5×	58 0.6×	42	872
Kathrin I. Foerster Germany	13	77 0.5×	18 0.2×	26 0.2×	48 0.4×	105 1.0×	39	651
Sarah Shugarts United States	9	63 0.4×	47 0.4×	17 0.1×	119 1.0×	85 0.8×	13	691
Elodie Gautier‐Veyret France	16	123 0.9×	32 0.3×	17 0.1×	63 0.5×	120 1.2×	39	657
Marina Kacevska Australia	14	97 0.7×	16 0.1×	42 0.4×	160 1.4×	66 0.6×	14	1.2k
Jiřina Martı́nková Czechia	16	145 1.0×	18 0.2×	23 0.2×	112 1.0×	83 0.8×	45	693
Jutta Miller United States	12	120 0.9×	14 0.1×	53 0.4×	103 0.9×	21 0.2×	20	483
C Grönhagen-Riska Finland	19	47 0.3×	56 0.5×	17 0.1×	27 0.2×	35 0.3×	34	886
M B Affrime United States	14	138 1.0×	12 0.1×	54 0.5×	91 0.8×	171 1.6×	46	765

Countries citing papers authored by Bindu Murthy

Since Specialization

Citations

This map shows the geographic impact of Bindu Murthy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bindu Murthy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bindu Murthy more than expected).

Fields of papers citing papers by Bindu Murthy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bindu Murthy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bindu Murthy. The network helps show where Bindu Murthy may publish in the future.

Co-authorship network of co-authors of Bindu Murthy

This figure shows the co-authorship network connecting the top 25 collaborators of Bindu Murthy. A scholar is included among the top collaborators of Bindu Murthy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bindu Murthy. Bindu Murthy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Emery, Paul, R. Fleischmann, Robert Wong, et al.. (2025). Association Between Abatacept Exposure Levels and Infection Occurrence in Patients With Rheumatoid Arthritis: Post Hoc Analysis of the AVERT-2 Study. The Journal of Rheumatology. 52(5). 426–435.

Perera, Vidya, Joseph M. Luettgen, Ronald Aronson, et al.. (2024). Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants. Scientific Reports. 14(1). 16591–16591.

Byon, Wonkyung, Yogesh T. Patel, Vidya Perera, et al.. (2023). Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder. CPT Pharmacometrics & Systems Pharmacology. 12(4). 500–512. 7 indexed citations

Dockens, Randy, et al.. (2023). Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects. Dermatology and Therapy. 13(12). 3153–3164. 3 indexed citations

Chimalakonda, Anjaneya, Wenying Li, Bing He, et al.. (2023). Absolute and Relative Bioavailability of Oral Solid Dosage Formulations of Deucravacitinib in Humans. Clinical Pharmacology in Drug Development. 12(10). 956–965. 2 indexed citations

Zhao, Yue, Kinjal Sanghavi, Amit Roy, et al.. (2023). Model‐Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors. Clinical Pharmacology & Therapeutics. 115(3). 488–497. 7 indexed citations

Perera, Vidya, Zhaoqing Wang, Lisa J. Christopher, et al.. (2022). Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor. Cardiology and Therapy. 11(3). 407–419. 18 indexed citations

Perera, Vidya, Danshi Li, Zhaoqing Wang, et al.. (2022). Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants. Clinical Pharmacokinetics. 61(6). 857–867. 25 indexed citations

Perera, Vidya, Zhaoqing Wang, Wei Chen, et al.. (2022). Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants. Scientific Reports. 12(1). 5165–5165. 13 indexed citations

10.

Perera, Vidya, Zhaoqing Wang, Lisa J. Christopher, et al.. (2022). Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor. Scientific Reports. 12(1). 22239–22239. 12 indexed citations

11.

Perera, Vidya, Danshi Li, Zhaoqing Wang, et al.. (2022). Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment. Clinical Pharmacokinetics. 61(10). 1405–1416. 13 indexed citations

12.

Perera, Vidya, Danshi Li, Zhaoqing Wang, et al.. (2021). SINGLE-DOSE PHARMACOKINETICS OF BMS-986177/JNJ-70033093 (BMS-177/JNJ-3093) IN PARTICIPANTS WITH NORMAL RENAL FUNCTION AND PARTICIPANTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT. Journal of the American College of Cardiology. 77(18). 1839–1839. 1 indexed citations

13.

Meah, Mohammed N., Jennifer Raftis, Simon Wilson, et al.. (2020). Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition. Arteriosclerosis Thrombosis and Vascular Biology. 40(11). 2678–2685. 13 indexed citations

14.

Garonzik, Samira M., et al.. (2019). The Effects of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Volunteers: A Single-Sequence Crossover Study. American Journal of Cardiovascular Drugs. 19(6). 561–567. 13 indexed citations

15.

Moudgil, Asha, Vikas R. Dharnidharka, Daniel I. Feig, et al.. (2018). Phase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients. American Journal of Transplantation. 19(4). 1218–1223. 13 indexed citations

16.

Xing, Jun, et al.. (2017). Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants. European Journal of Clinical Pharmacology. 73(6). 689–698. 26 indexed citations

17.

D’Agostino, Maria Antonietta, Rieke Alten, Eduardo Mysler, et al.. (2017). Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis. Clinical Rheumatology. 36(12). 2655–2665. 25 indexed citations

18.

Westhovens, René, Antônio Carlos Ximenes, J. Wollenhaupt, et al.. (2014). Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis. Annals of the Rheumatic Diseases. 74(3). 564–568. 35 indexed citations

19.

Nash, Peter, Charles Ludivico, I. Delaet, et al.. (2012). Efficacy, safety and pharmacokinetics of subcutaneous abatacept in patients with rheumatoid arthritis, with or without an intravenous loading dose. Lara D. Veeken. 42. 12–12. 4 indexed citations

20.

Burris, Howard A., David M. Berman, Bindu Murthy, & Suzanne F. Jones. (2010). Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations. Cancer Chemotherapy and Pharmacology. 67(5). 1045–1054. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact